Context Therapeutics
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2001 Market St Ste 3915 Unit 15, Philade...Phone Number
(267) 225-7416Website
www.contexttherapeutics.comRevenue
$5.1 MillionStock Symbol
CNTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Explore more
Context Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Context Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Context Therapeutics recently announced quarterly report
Context Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Context Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Context Therapeutics is spiking on competitors!
Check if Context Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Context Therapeutics
Click to see if Context Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Context Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Context Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Context Therapeutics
Compare insights from companies similar to Context Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Context Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Context Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Context Therapeutics.
Context Therapeutics financials insights
Gather financial insights about Context Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$31.3M
Context Therapeutics Tech Stack
A closer look at the technologies used by Context Therapeutics
Most Recent Scoops
Project
Spending/Investment, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals, Contracts, Finance
Project
Product Management, Legal Affairs, Medical Research, Pharmaceuticals, Regulations
Project
aims to enroll approximately 10 platinum-resistant ovarian patients who are ADC exposed at target dose levels by Q2, targeting a 30% response rate. This would compare favorably to standard of care (paclitaxel and doxorubicin) which has a 5% to 10% response rate and approximately 3-month PFS.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Context Therapeutics has three programs targeting Claudin-6, mesothelin, and Nectin-4. Claudin-6 and mesothelin are in the clinic with Phase 1a data expected in Q2 for Claudin-6 and mid of the year for mesothelin, while the Nectin-4 program will enter the clinic imminently.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research
Context Therapeutics News & Media
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable licenseContext Therapeutics Reports First Quarter 2026 Operating and Financial Results
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROCContext Therapeutics Reports Full Year 2025 Operating and Financial Results
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Context Therapeutics
Sign Up For FreeTo access detailed company insights
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreeme... Read More
